UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status

Frontiers in oncology, 2021-08, Vol.11, p.705911-705911

2021

Volltextzugriff (PDF)

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Clinical cancer research, 2019-05, Vol.25 (10), p.2975-2987

2019

Volltextzugriff (PDF)

The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer

Frontiers in immunology, 2021-11, Vol.12, p.784823-784823

2021

Volltextzugriff (PDF)

Updating the role of obesity and cholesterol in breast cancer

Breast cancer research : BCR, 2019-03, Vol.21 (1), p.35-35, Article 35

2019

Volltextzugriff (PDF)

Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy

Clinical cancer research, 2015-01, Vol.21 (2), p.322-328

2015

Volltextzugriff (PDF)

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.884-890

2018

Volltextzugriff (PDF)

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays

Journal of surgical oncology, 2017-05, Vol.115 (6), p.647-662

2017

Volltextzugriff (PDF)

Predictive Role of Leptin Receptor (Ob-R) Overexpression in Patients with Early Breast Cancer Receiving Neoadjuvant Systemic Treatment

Cancers, 2021-06, Vol.13 (13), p.3269

2021

Volltextzugriff (PDF)

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The lancet oncology, 2017-10, Vol.18 (10), p.1360-1372

2017

Volltextzugriff (PDF)

Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients

Cancer treatment reviews, 2020-02, Vol.83, p.101944-101944, Article 101944

2020

Volltextzugriff (PDF)

Experience with eribulin in patients with metastatic breast cancer and associated hepatic impairment: case studies

Future oncology (London, England), 2018-03, Vol.14 (7s), p.29-36

2018

Volltextzugriff (PDF)

Novel therapeutic approaches to the treatment of metastatic breast cancer

Cancer treatment reviews, 2010-02, Vol.36 (1), p.33-42

2010

Volltextzugriff (PDF)

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

Anti-cancer drugs, 2012-02, Vol.23 (2), p.239-246

2012

Volltextzugriff (PDF)

Enhancing global access to cancer medicines

CA: a cancer journal for clinicians, 2020-03, Vol.70 (2), p.105-124

2020

Volltextzugriff (PDF)

Supportive care for patients with early breast cancer

Clinical & translational oncology, 2010, Vol.12 (1), p.32-42

2010

Volltextzugriff (PDF)

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer

Clinical cancer research, 2020-12, Vol.26 (23), p.6149-6157

2020

Volltextzugriff (PDF)

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

International journal of molecular sciences, 2024-04, Vol.25 (7), p.3940

2024

Volltextzugriff (PDF)

Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.568-568

2016

Volltextzugriff (PDF)

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)

Journal of clinical oncology, 2022-02, Vol.40 (5), p.449-458

2022

Volltextzugriff (PDF)

Abstract P5-13-18: Upregulation of immune response biomarkers by ribociclib plus endocrine therapy (ET) in paired tumor samples from phase I studies

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-18

2022

Volltextzugriff (PDF)

Effect of Oncotype DX Recurrence Score (RS) on chemotherapy (CT) decision-making by providing information beyond intrinsic subtypes in both luminal A and B breast cancer (BC) patients (pts): A retrospective study in the Spanish population

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e12013-e12013

2016

Volltextzugriff (PDF)

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)

Breast (Edinburgh), 2019-06, Vol.45, p.7-14

2019

Volltextzugriff (PDF)

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

European journal of cancer (1990), 2017-09, Vol.82, p.237-246

2017

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(44)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Oncology
(24)
Humans
(21)
Female
(20)
Breast Cancer
(13)
Breast Neoplasms - Drug Therapy
(12)
Breast Neoplasms - Pathology
(10)
Chemotherapy
(8)
Adult
(7)
Middle Aged
(7)
Aged
(5)
Cancer Therapies
(5)
Neoplasm Metastasis
(5)
Patients
(5)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(4)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(4)
Breast Neoplasms - Genetics
(4)
Cancer
(4)
Medicine
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer

Updating the role of obesity and cholesterol in breast cancer

Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays

Predictive Role of Leptin Receptor (Ob-R) Overexpression in Patients with Early Breast Cancer Receiving Neoadjuvant Systemic Treatment

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients

Experience with eribulin in patients with metastatic breast cancer and associated hepatic impairment: case studies

Novel therapeutic approaches to the treatment of metastatic breast cancer

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

Enhancing global access to cancer medicines

Supportive care for patients with early breast cancer

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)

Abstract P5-13-18: Upregulation of immune response biomarkers by ribociclib plus endocrine therapy (ET) in paired tumor samples from phase I studies

Effect of Oncotype DX Recurrence Score (RS) on chemotherapy (CT) decision-making by providing information beyond intrinsic subtypes in both luminal A and B breast cancer (BC) patients (pts): A retrospective study in the Spanish population

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)

Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Suchergebnisse filtern